- Home
- DNP vs TMDX Comparison
DNP vs TMDX Comparison
Compare DNP & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNP
- TMDX
- Stock Information
- Founded
- DNP 1986
- TMDX 1998
- Country
- DNP United States
- TMDX United States
- Employees
- DNP N/A
- TMDX N/A
- Industry
- DNP Investment Managers
- TMDX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- DNP Finance
- TMDX Health Care
- Exchange
- DNP Nasdaq
- TMDX Nasdaq
- Market Cap
- DNP 3.8B
- TMDX 4.0B
- IPO Year
- DNP N/A
- TMDX 2019
- Fundamental
- Price
- DNP $10.19
- TMDX $123.18
- Analyst Decision
- DNP
- TMDX Buy
- Analyst Count
- DNP 0
- TMDX 11
- Target Price
- DNP N/A
- TMDX $130.73
- AVG Volume (30 Days)
- DNP 479.6K
- TMDX 1.1M
- Earning Date
- DNP 01-01-0001
- TMDX 10-29-2025
- Dividend Yield
- DNP 7.88%
- TMDX N/A
- EPS Growth
- DNP N/A
- TMDX 170.70
- EPS
- DNP 2.30
- TMDX 2.54
- Revenue
- DNP $154,887,179.00
- TMDX $566,354,000.00
- Revenue This Year
- DNP N/A
- TMDX $38.84
- Revenue Next Year
- DNP N/A
- TMDX $20.46
- P/E Ratio
- DNP $4.26
- TMDX $48.26
- Revenue Growth
- DNP 3.30
- TMDX 41.20
- 52 Week Low
- DNP $8.69
- TMDX $55.00
- 52 Week High
- DNP $10.04
- TMDX $145.50
- Technical
- Relative Strength Index (RSI)
- DNP 58.36
- TMDX 51.08
- Support Level
- DNP $9.96
- TMDX $115.21
- Resistance Level
- DNP $10.22
- TMDX $125.57
- Average True Range (ATR)
- DNP 0.10
- TMDX 7.60
- MACD
- DNP 0.00
- TMDX -0.96
- Stochastic Oscillator
- DNP 78.90
- TMDX 32.09
About DNP DNP Select Income Fund Inc.
DNP Select Income Fund Inc is a closed-ended investment management fund. The primary investment objectives of the fund are current income and long-term growth of income. Its secondary objective is capital appreciation. The Fund seeks to achieve its investment objectives by investing in the public utility industry.
About TMDX TransMedics Group Inc.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.